Tagged with P

Global Cell and gene therapies are redefining the boundaries of what is scientifically and operationally possible in healthcare, but bringing these innovations to patients at scale requires more than breakthrough science. In this conversation, Ralf Altenburger, Global Head of Cell & Gene Therapy at Roche, discusses how the company is navigating…

Global Whether in the corridors of the FDA or the fast-evolving frameworks of ANVISA in Brazil, regulators around the world are undergoing a quiet revolution. While mature markets like the US and Europe double down on digitalisation and real-world evidence, emerging players like Brazil and China are accelerating access and joining…

Denmark As European biotech continues to navigate tightening capital markets and increasing global competition, Kurma Partners is doubling down on its core belief: that world-class innovation can, and should, be built and scaled from within Europe. Managing Partner Rémi Droller shares how Kurma’s investment model combines early-stage company creation with long-term…

China Chinese biotech is booming, led by a generation of pioneering individuals at the forefront of science and business.   A country once best known as a low-cost manufacturing destination for ‘me-too’ copycat medicines now accounts for over 28 percent of the global drug development pipeline. Western companies approaching patent cliffs…

Global As the global population ages and the incidence of vision-related conditions rises, ophthalmology is entering a transformative era. Beyond symptom management, the field is moving towards disease modification through cell and gene therapies like optogenetics while boosting artificial intelligence (AI) to speed up pipelines, and developing minimally invasive delivery systems…

China Dr Ben Zhao, Chief Executive Officer and co-founder of Haichang Biotechnology (HCBio, Haichang), represents a new paradigm in pharmaceutical innovation, bridging regulatory expertise with entrepreneurial vision. Having transitioned from a distinguished career at the FDA to establishing one of the most promising lipid nanoparticle delivery platforms in the industry, he…

USA The latest stories from healthcare and the life sciences in the US. The FDA names Stanford’s George Tidmarsh as the new head of CDER; AstraZeneca commits USD 50 billion to new US manufacturing and R&D projects; Moderna cancels its planned mRNA facility in Japan; Sarepta refuses to halt Elevidys shipments…

Puerto Rico In cell and gene therapy, where R&D and manufacturing are inseparable, Puerto Rico’s strong biopharma base makes it an attractive option for CGT companies.   The first mover in this space is CytoImmune. Founded in 2017 by a cadre of Big Pharma veterans and established in Puerto Rico in 2020,…

Puerto Rico Despite being a small island in the Caribbean, measuring just 100 by 35 miles, Puerto Rico has long punched above its weight as an industrial powerhouse. Already a leading producer of everything from blockbuster medicines to high-tech medical devices, how has it got to this point and what comes next?…

Puerto Rico Spending almost 30 years working for a single company is almost unheard of in today’s life science industry, where executives chop and change between firms with bewildering frequency.   However, in CooperVision – one of the world’s leading soft contact lens manufacturers with Puerto Rico at its beating heart –…

Puerto Rico The largest pharmaceutical hub in the Americas, Puerto Rico currently exports to 120 countries, accounting for nearly USD 53 billion in weekly biopharma shipments. Remarkably, this small Caribbean island out-exports all individual US states, shipping out over twice as much as second-placed Indiana. The life sciences industry is central to this…

Puerto Rico Long celebrated for its world-class pharmaceutical and medical device manufacturing, Puerto Rico is now leveraging this strong foundation to nurture a new era of research and development. Rather than shifting away from production, the island is integrating R&D directly into its manufacturing operations — from pilot plants and small-scale prototyping…